News
There is a continuing need for effective vaccinations against viruses which specifically infect the liver. According to the World Health Organization WHO, approximately 400 million people around the world are infected by hepatitis B or hepatitis C viruses and approximately 1.4 million people succumb to them each year. Moreover, chronic hepatitis B or C infections are amongst the most common causes of liver cancer and therefore are some of the most common reasons for a liver transplantation. Recently, a research team directed by Prof Dunja Bruder, who holds appointments at both the Helmholtz Centre for Infection Research (HZI) and the Otto von Guericke University Magdeburg, successfully targeted a vaccine specifically to recognition molecules of certain immune cells which allowed them to elicit an effective immune defence in the liver. The researchers published their results in Scientific Reports.